According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- the quality and integrity of the scientific data supporting Cassava Sciences’ claims for the efficacy of simufilam, a small molecule drug designed to treat Alzheimer’s disease, had been overstated;
- the scientific data supporting Cassava Sciences’ claims for simufilam’s efficacy were biased; and
- as a result of the foregoing, defendants’ positive statements during the Class Period about the Company’s business metrics and financial prospects and the likelihood of U.S. Food and Drug Administration (“FDA”) approval were false and misleading and/or lacked a reasonable basis.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
